1. ISCHAEMIC CARDIOMYOPATHYREVASCULARISATION-HOW WHEN AND WHY?Dr. DEV PAHLAJANI (MD,FACC,FSCAI) HOD INTERVENTIONAL CARDIOLOGY BREACH CANDYHOSPITAL ANDCONSULTANT CARDIOLOGIST…

Slide 1© 2007 Cardinal Health. All rights reserved. PET In Cardiology; Metabolic Imaging with 18-FDG Slide 2 © 2007 Cardinal Health. All rights reserved. Introduction to…

Slide 1Assessment of Cardiac Viability Joyce Meng M.D. 8/15/2007 Slide 2 Viability-some definitions The most practical definition of viability is “myocardium that demonstrates…

1. ScientificProgram 2. 15 Wednesday, 01/Oct/20149:00 - 9:45Basic ScienceSession 1ChairpersonsAbdel Fattah Kholeif Hesham El AshmawyMohsen Ibrahim Saeed KandilSamir Rafla…

1. 123. Kushner F.G., Hand M., Smith S.C. et al. 124. Antoniucci D. JETSTENT trial results:2009 Focused updates: ACC/AHA guidelines for the impact on ST-segment elevation…

1. iMaging 5.0: Our Newest Radiology Operating System Unleashed Kenneth L. Pierce, M.D. Associate Professor Stritch School of Medicine 2. iMaging 5.0: What’s New? • PACS…

1. The hibernating myocardium 2. • Concerted efforts to reduce the global burden of cardiovascular disease over the past three decades have reduced mortality from coronary…

Slide 1 Stem Cells in cardiovascular diseases Arshed A. Quyyumi MD; FRCP Professor of Medicine Division of Cardiology Emory University School of Medicine Atlanta, Georgia,…

Slide 1 iMaging 5.0: Our Newest Radiology Operating System Unleashed Kenneth L. Pierce, M.D. Associate Professor Stritch School of Medicine Slide 2 iMaging 5.0: What’s…

Slide 1 PHARMACOLOGICAL TREATMENT OF ISCHAEMIC HEART DISEASE 1. Definition of myocardial ischaemia "The blood supply to the myocardium is inadequate" (Opie) "The…